ABSTRACT

Objectives

Anxiety disorders are highly prevalent in adults, and commonly aggregate within families. Although cognitive behavioural therapy (CBT) is regarded the most efficacious psychotherapy for anxiety disorders, remission rates are sub-optimal and broader systemic factors are typically not considered. The present study examined the acceptability of a modified transdiagnostic CBT for adult anxiety that also targeted anxiety-maintaining parenting behaviours and cognitions in anxious adults parenting an anxious child.

Methods

Ten anxious adults (M age = 39.5, SD = 2.9) parenting an anxious child (M age = 8.5, SD = 1.4) were interviewed. Five parents who received the intervention and five parents interested in the intervention provided retrospective and prospective perceptions of intervention acceptability, along with perspectives on bidirectional parent–child factors relevant to anxiety symptom maintenance. Responses were analysed using a reflexive thematic analysis.

Results

Six themes emerged showing the intervention was perceived as beneficial and effective for reducing parents’ own anxiety and managing bidirectional anxiety maintaining factors in the parent-child dyad.

Conclusions

Parents’ rich perspectives elucidate the aspects of the intervention that are important to this underrepresented population. Further, targeting an adult’s anxiety in a systemic context was valued by anxious adults parenting an anxious child, providing a rationale for broader evaluation. Trial prospectively registered, ANZCTR1261900033410, 04 March 2019.

中文翻译：

---

增强型跨诊断 CBT 干预对抚养焦虑儿童的焦虑症成人的可接受性

摘要

目标

焦虑症在成人中非常普遍，并且通常在家庭中聚集。尽管认知行为疗法 (CBT) 被认为是治疗焦虑症最有效的心理疗法，但缓解率并不理想，并且通常不考虑更广泛的全身因素。本研究检查了改进的跨诊断 CBT 对成人焦虑的可接受性，该 CBT 还针对焦虑的成年人养育焦虑孩子的焦虑维持育儿行为和认知。

方法

采访了十名焦虑的成年人（M 年龄 = 39.5，SD = 2.9）抚养一个焦虑的孩子（M 年龄 = 8.5，SD = 1.4）。五名接受干预的父母和五名对干预感兴趣的父母提供了对干预可接受性的回顾性和前瞻性看法，以及与焦虑症状维持相关的双向亲子因素的观点。使用反身主题分析分析反应。

结果

出现了六个主题，表明干预被认为对减少父母自身的焦虑和管理亲子关系中的双向焦虑维持因素是有益和有效的。

结论

父母丰富的观点阐明了干预措施对这一代表性不足的人群很重要的方面。此外，在系统性背景下针对成年人的焦虑，焦虑的成年人养育焦虑的孩子，这为更广泛的评估提供了依据。前瞻性注册试验，ANZCTR1261900033410，2019 年 3 月 4 日。